Table 1.
Clinicopathological features of 21 patients with fibrolamellar hepatocellular carcinoma.
| Characteristics | All patients |
|---|---|
| Age (years, median, range) | 20 (13 – 49) |
| Gender (male/female, %) | 33/67 |
| Tumor staging (TNM, n, %) | |
| I or II | 6 (28%) |
| III or IV | 15 (72%) |
| Tumor size (cm, median, range) | 12 (6 – 19) |
| Tumor size>10 cm (n, %)* | 13 (68%) |
| Vascular invasion (n, %)* | 8 (42%) |
| Microvascular invasion | 3 (16%) |
| Macrovascular invasion | 5 (26%) |
| Extra-hepatic metastasis (n, %) | 13 (62%) |
| Treatment (n, %) | |
| Surgery | 9 (43%) |
| Surgery + systemic therapy | 5 (24%) |
| QT Chemotherapy | 3 (14%) |
| Palliative care | 4 (19%) |
| Recurrence (n, %)** | 8 (80%) |
| Site of recurrence (n, %) | |
| Liver | 3 (38%) |
| Lymph node | 3 (38%) |
| Liver and lymph node | 1 (12%) |
| Peritoneal implants | 1 (12%) |
| Histology (n, %) | |
| Pure fibrolamellar hepatocellular carcinoma | 18 (86%) |
| Mixed fibrolamellar hepatocellular carcinoma | 3 (14%) |
*Tumor size and vascular invasion were evaluated in 19 patients; ** Recurrence was evaluated in 10 patients.